Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2012. The report details a specific corporate action regarding share repurchases executed on May 23, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share capital movements.
- Shares Purchased: 1,800,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,409.0 pence per share; lowest price paid was 1,390.0 pence per share.
- Treasury Holdings (Settled): 536,147,927 shares (9.63% of total issued share capital).
- Treasury Holdings (Including Unsettled): 541,547,927 shares (10.77% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,028,537,676 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,800,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 10.77% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the 1,800,000 share repurchase based on the weighted average price between 1,390.0 and 1,409.0 pence.
- Confirm the impact of the 10.77% Treasury holding on the denominator for shareholder notification thresholds under Disclosure and Transparency Rules.
- Check subsequent filings to confirm the settlement of the 5,400,000 shares (difference between settled and total Treasury holdings) mentioned as "purchased but not yet settled."